Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of IVX-A12 VLP Vaccine in Older Adults
jRCT2031240264Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2025
- Modality
- Vaccines & Immunotherapeutics, Nanoparticles → Drug Delivery Systems
01
Overview
Phase 3, randomised, double-blind trial in respiratory syncytial virus lower respiratory tract infection and Human metapneumovirus lower respiratory tract disease comparing IVX-A12 with Placebo (2 arms). Primary endpoints: RSV-confirmed LRTD incidence in first season and hMPV-confirmed LRTD incidence in first season. Started Aug 2025; status: completed.
02
Drugs
IVX-A12
03
Conditions
respiratory syncytial virus lower respiratory tract infectionHuman metapneumovirus lower respiratory tract disease
Beyond the preview
Go deeper on jRCT2031240264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240264.